Struggling The Medicines Company Deals Its Infectious Disease Biz to Melinta for $270M Post author:Sam Post published:November 28, 2017 Post category:BioPharma The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics. Source: BioSpace You Might Also Like Ipsen Announces FDA Approval Of Dysport (Abobotulinumtoxina) For The Treatment Of Lower Limb Spasticity In Adults June 15, 2017 SI-BONE Announces Published Guidance Recommendation For Minimally Invasive SI Joint Fusion From The SI-BONE April 6, 2017 Siemens to Replace Healthineers CFO in Preparation for Listing November 8, 2017
Ipsen Announces FDA Approval Of Dysport (Abobotulinumtoxina) For The Treatment Of Lower Limb Spasticity In Adults June 15, 2017
SI-BONE Announces Published Guidance Recommendation For Minimally Invasive SI Joint Fusion From The SI-BONE April 6, 2017